Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain.

Ittai Bushlin | Achla Gupta | Steven D Stockton | Lydia K Miller | Lakshmi A Devi
PloS one | 2012

The diversity of receptor signaling is increased by receptor heteromerization leading to dynamic regulation of receptor function. While a number of studies have demonstrated that family A G-protein-coupled receptors are capable of forming heteromers in vitro, the role of these heteromers in normal physiology and disease has been poorly explored. In this study, direct interactions between CB(1) cannabinoid and delta opioid receptors in the brain were examined. Additionally, regulation of heteromer levels and signaling in a rodent model of neuropathic pain was explored. First we examined changes in the expression, function and interaction of these receptors in the cerebral cortex of rats with a peripheral nerve lesion that resulted in neuropathic pain. We found that, following the peripheral nerve lesion, the expression of both cannabinoid type 1 receptor (CB(1)R) and the delta opioid receptor (DOR) are increased in select brain regions. Concomitantly, an increase in CB(1)R activity and decrease in DOR activity was observed. We hypothesize that this decrease in DOR activity could be due to heteromeric interactions between these two receptors. Using a CB(1)R-DOR heteromer-specific antibody, we found increased levels of CB(1)R-DOR heteromer protein in the cortex of neuropathic animals. We subsequently examined the functionality of these heteromers by testing whether low, non-signaling doses of CB(1)R ligands influenced DOR signaling in the cortex. We found that, in cortical membranes from animals that experienced neuropathic pain, non-signaling doses of CB(1)R ligands significantly enhanced DOR activity. Moreover, this activity is selectively blocked by a heteromer-specific antibody. Together, these results demonstrate an important role for CB(1)R-DOR heteromers in altered cortical function of DOR during neuropathic pain. Moreover, they suggest the possibility that a novel heteromer-directed therapeutic strategy for enhancing DOR activity, could potentially be employed to reduce anxiety associated with chronic pain.

Pubmed ID: 23272051

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIDA NIH HHS, United States
    Id: R37 DA008863
  • Agency: NIDA NIH HHS, United States
    Id: K05 DA019521
  • Agency: NIGMS NIH HHS, United States
    Id: T32 GM062754
  • Agency: NIGMS NIH HHS, United States
    Id: T32GM062754
  • Agency: NIDA NIH HHS, United States
    Id: R01 DA008863
  • Agency: NIDA NIH HHS, United States
    Id: DA008863
  • Agency: NIDA NIH HHS, United States
    Id: DA019521
  • Agency: NIDA NIH HHS, United States
    Id: R56 DA008863
  • Agency: NIGMS NIH HHS, United States
    Id: 1P50GM071558-01A27398

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


SD (tool)

RRID:RGD_70508

Rattus norvegicus with name SD from RGD.

View all literature mentions